摘要
目的观察美沙拉秦联合培菲康治疗轻、中度溃疡性结肠炎的临床效果。方法将确诊的78例轻、中度溃疡性结肠炎患者随机分为治疗组(n=40),采用美沙拉秦缓释颗粒每次1.0 g,每天4次,联合培菲康胶囊每次420 mg,每天3次进行治疗;对照组(n=38)美沙拉秦缓释颗粒用法同治疗组。疗程8周。观察两组治疗前后临床症状变化情况,根据结肠镜检查结果分析疗效。结果治疗组临床症状较对照组明显改善,总有效率和对照组相比差异有统计学意义。结论美沙拉秦联合培菲康治疗轻、中度溃疡性结肠炎临床疗效显著,不良反应少,较单用美沙拉秦能更好改善患者的临床症状。
Objective To observe the clinical effect of mesalazine combined with bifico in patients with mild to moderate ulcerative colitis. Methods 78 definite patients were randomly divided into two groups. The treatment group（ n = 40 ） was given Mesalazine SR Granules 1.0, orally four times a day, and bifico 420 rag, orally three times a day,while patients in the control group（ n = 38）were given the same dose of Mesalazine SR Granules as the treatment group for 8 weeks. The changes of clinical symptoms were evaluated before and after treatment. The therapeutic effect was analyzed according to the results of colonoscopy. Results Clinical symptoms were relieved more significantly in treatment group than in control group. The total effective rate of treatment group was significantly higher than that in control group. Conclusion The clinical effect of mesalazine combined with bifico in treatment of mild to moderate active UC is remarkable and more effective than mesalazine alone, with fewer adverse reactions.
出处
《解放军药学学报》
CAS
2012年第5期461-463,共3页
Pharmaceutical Journal of Chinese People's Liberation Army
